117 related articles for article (PubMed ID: 19364653)
21. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Kamdem LK; Xi J; Clark BL; Gregory BJ; Kidwell KM; Storniolo AM; Stearns V; Hayes DF; Gersch CL; Rae JM; Henry NL; Hertz DL
Breast Cancer Res Treat; 2019 Jun; 175(2):297-303. PubMed ID: 30747308
[TBL] [Abstract][Full Text] [Related]
22. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
23. Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan.
Yoneda K; Tanji Y; Ikeda N; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
Cancer Lett; 2002 Dec; 186(2):223-30. PubMed ID: 12213292
[TBL] [Abstract][Full Text] [Related]
24. Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
Berruti A; Tucci M; Mosca A; Vana F; Ardine M; Dogliotti L; Angeli A; Bertoldo F
J Clin Oncol; 2007 Apr; 25(11):1455-6. PubMed ID: 17416873
[No Abstract] [Full Text] [Related]
25. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
Lønning PE; Geisler J; Krag LE; Erikstein B; Bremnes Y; Hagen AI; Schlichting E; Lien EA; Ofjord ES; Paolini J; Polli A; Massimini G
J Clin Oncol; 2005 Aug; 23(22):5126-37. PubMed ID: 15983390
[TBL] [Abstract][Full Text] [Related]
26. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
Montagnani A; Gonnelli S; Cadirni A; Caffarelli C; Del Santo K; Pieropan C; Campagna MS; Montomoli M; Petrioli R; Nuti R
Eur J Intern Med; 2008 Dec; 19(8):592-7. PubMed ID: 19046724
[TBL] [Abstract][Full Text] [Related]
27. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
Decensi A; Sun Z; Guerrieri-Gonzaga A; Thürlimann B; McIntosh C; Tondini C; Monnier A; Campone M; Debled M; Schönenberger A; Zaman K; Johansson H; Price KN; Gelber RD; Goldhirsch A; Coates AS; Aebi S
Breast Cancer Res Treat; 2014 Apr; 144(2):321-9. PubMed ID: 24487691
[TBL] [Abstract][Full Text] [Related]
28. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.
McCloskey EV; Hannon RA; Lakner G; Fraser WD; Clack G; Miyamoto A; Finkelman RD; Eastell R
Eur J Cancer; 2007 Nov; 43(17):2523-31. PubMed ID: 18029171
[TBL] [Abstract][Full Text] [Related]
29. Exemestane or tamoxifen?
Ueda M; Toji E; Noda S
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
[No Abstract] [Full Text] [Related]
30. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women.
Cigler T; Richardson H; Yaffe MJ; Fabian CJ; Johnston D; Ingle JN; Nassif E; Brunner RL; Wood ME; Pater JL; Hu H; Qi S; Tu D; Goss PE
Breast Cancer Res Treat; 2011 Apr; 126(2):453-61. PubMed ID: 21221773
[TBL] [Abstract][Full Text] [Related]
31. Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.
Chow LW; Yip AY; Chu WP; Loo WT; Toi M
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):112-9. PubMed ID: 21236344
[TBL] [Abstract][Full Text] [Related]
32. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant treatment of breast cancer with exemestane.
Tanvetyanon T
N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15237463
[No Abstract] [Full Text] [Related]
34. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
35. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
Jones S; Stokoe C; Sborov M; Braun M; Ethirajan S; Kutteh L; Pippen J; Patel M; Paul D; Blum JL; Holmes FA; Myron MC; Cantrell J; Hartung NL; Look RM; Di Salle E; Davis JC; Ilegbodu D; Asmar L
Clin Breast Cancer; 2008 Dec; 8(6):527-32. PubMed ID: 19073509
[TBL] [Abstract][Full Text] [Related]
36. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.
Marttunen MB; Hietanen P; Tiitinen A; Ylikorkala O
J Clin Endocrinol Metab; 1998 Apr; 83(4):1158-62. PubMed ID: 9543133
[TBL] [Abstract][Full Text] [Related]
37. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
38. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Coombes RC; Kilburn LS; Snowdon CF; Paridaens R; Coleman RE; Jones SE; Jassem J; Van de Velde CJ; Delozier T; Alvarez I; Del Mastro L; Ortmann O; Diedrich K; Coates AS; Bajetta E; Holmberg SB; Dodwell D; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Forbes J; Castiglione M; Stuart N; Stewart A; Fallowfield LJ; Bertelli G; Hall E; Bogle RG; Carpentieri M; Colajori E; Subar M; Ireland E; Bliss JM;
Lancet; 2007 Feb; 369(9561):559-70. PubMed ID: 17307102
[TBL] [Abstract][Full Text] [Related]
39. Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate.
Martinetti A; Zilembo N; Ferrari L; Massimini G; Polli A; La Torre I; Giovanazzi R; Pozzi P; Bidoli P; De Candis D; Seregni E; Bombardieri E; Bajetta E
Anticancer Res; 2003; 23(4):3485-91. PubMed ID: 12926095
[TBL] [Abstract][Full Text] [Related]
40. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Goss PE
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
